Results 21 to 30 of about 4,836 (234)

Efficacy of Imipenem/Cilastatin/Relebactam in infections caused by Difficult-to-Treat Gram-Negative Bacteria: A Retrospective Analysis of Real-world data in Greece. [PDF]

Infez Med
Background The escalating global crisis of antimicrobial resistance (AMR), particularly among multidrug-resistant (MDR) Gram-negative bacteria (GNB), presents a significant challenge to patient care.
Petrakis V, Rafailidis P, Panopoulou M, Konstantinidis T, Babaka N, Papazoglou D, Panagopoulos P.   +6 more
europepmc   +2 more sources

Empiric Imipenem/Cilastatin/Relebactam for Febrile Neutropenia After Allogeneic Hematopoietic Stem Cell Transplantation: Two Case Reports [PDF]

Journal of Blood Medicine
Dao-Xing Deng,* Ting Wang,* Hui Sun,* Jun Kong, Yuan-Yuan Zhang, Le-Qing Cao, Xiao-Dong Mo Department of Hematology, Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center
Deng DX, Wang T, Sun H, Kong J, Zhang YY, Cao LQ, Mo XD   +6 more
doaj   +2 more sources

Real-World Experience of Imipenem–Relebactam Treatment as Salvage Therapy in Difficult-to-Treat Pseudomonas aeruginosa Infections (IMRECOR Study) [PDF]

Infectious Diseases and Therapy
Introduction Difficult-to-treat-resistant (DTR) infections caused by Pseudomonas aeruginosa represent a global public health threat, prioritizing the search and development of new antibiotics for this microorganism.
Isabel Machuca, Arantxa Dominguez, Rosario Amaya, Cristina Arjona, Irene Gracia-Ahufinger, Maravillas Carralon, Rosa Giron, Isabel Gea, Natividad De Benito, Andres Martin, Fatima Galan, Jose Antonio Martinez, Rayden Iglesias, Jaume Revuelto, Juan Jose Caston, Angela Cano, Elisa Ruiz-Arabi, Luis Martínez-Martínez, Julian Torre-Cisneros   +18 more
doaj   +2 more sources

Aztreonam Combinations with Avibactam, Relebactam, and Vaborbactam as Treatment for New Delhi Metallo-β-Lactamase-Producing Enterobacterales Infections—In Vitro Susceptibility Testing

Pharmaceuticals
Antimicrobial resistance is a major global health issue. Metallo-β-lactamases (MBL), in particular, are problematic because they can inactivate all classes of β-lactams except aztreonam.
Małgorzata Brauncajs, Filip Bielec, Marlena Malinowska, Dorota Pastuszak-Lewandoska   +3 more
doaj   +2 more sources

AmpC induction by imipenem in Pseudomonas aeruginosa occurs in the absence of OprD and impacts imipenem/relebactam susceptibility

Microbiology Spectrum
In the United States, carbapenem resistance in Pseudomonas aeruginosa is linked to the regulation of chromosomal resistance determinants, AmpC and OprD.
Shawn Freed, Jr, Nancy D. Hanson
doaj   +2 more sources

Clinical imipenem non-susceptible Klebsiella pneumoniae isolates from China: Epidemiology, molecular characterization and in vitro activity of imipenem/relebactam

Journal of Global Antimicrobial Resistance
Objective: To describe the epidemiological and molecular characterization and in vitro activity of imipenem/relebactam against imipenem non-susceptible (IPMNS) Klebsiella pneumoniae isolates in China. Methods: K.
Peiyao Jia, Pengcheng Li, Wei Yu, Xiaobing Chu, Hui Zhang, Jingjia Zhang, Wei Kang, Ge Zhang, Qian Zhang, Shiyu Chen, Yingchun Xu, Qiwen Yang   +11 more
doaj   +2 more sources

Early Multicenter Experience With Imipenem-Cilastatin-Relebactam for Multidrug-Resistant Gram-Negative Infections [PDF]

Open Forum Infectious Diseases, 2021
A multicenter case series of 21 patients were treated with imipenem-cilastatin-relebactam. There were mixed infection sources, with pulmonary infections (11/21,52%) composing the majority. The primary pathogen was Pseudomonas aeruginosa (16/21, 76%), and
Alosaimy, Sara, Lagnf, Abdalhamid M., Morrisette, Taylor, Rebold, Nicholas   +3 more
core   +5 more sources

Real-world use of imipenem/cilastatin/relebactam for the treatment of KPC-producing Klebsiella pneumoniae complex and difficult-to-treat resistance (DTR) Pseudomonas aeruginosa infections. A single-center preliminary experience [PDF]

Frontiers in Microbiology
Introduction: Real-life experience with imipenem/cilastatin/relebactam (IMI/REL) for the treatment of KPC-producing Klebsiella pneumoniae complex (KPC-Kp) and difficult-to-treat resistance (DTR) Pseudomonas aeruginosa (DTR-PA) infections is herein ...
Cancelli, Francesca, Carnevalini, Martina, Covino, Sara, Falletta, Antonio, Franchi, Cristiana, Leanza, Cristiana, Mascellino, Maria Teresa, Mastroianni, Claudio M, Oliva, Alessandra, Volpicelli, Lorenzo   +9 more
core   +2 more sources

Real-world evaluation of imipenem/cilastatin/relebactam across US medical centres

Journal of Global Antimicrobial Resistance
We assessed 160 patients who received imipenem/cilastatin/relebactam for ≥2 days. At treatment initiation, the median Charlson Comorbidity Index was 5, 45% were in the intensive care unit, and 19% required vasopressor support.
Ryan K. Shields, Emre Yücel, Vladimir Turzhitsky, Sanjay Merchant, Jae S. Min, Alexandre H. Watanabe   +5 more
doaj   +3 more sources

Mutant prevention concentrations, in vitro resistance evolution dynamics, and mechanisms of resistance to imipenem and imipenem/relebactam in carbapenem-susceptible Klebsiella pneumoniae isolates showing ceftazidime/avibactam resistance [PDF]

Antimicrobial Agents and Chemotherapy
[Abstract] Klebsiella pneumoniae carbapenemase (KPC) variants selected during ceftazidime/avibactam treatment usually develop susceptibility to carbapenems and carbapenem/β-lactamase inhibitors, such as imipenem and imipenem/relebactam.
Aja-Macaya, Pablo, Alonso-García, Isaac, Arca-Suárez, Jorge, Beceiro, Alejandro, Blanco-Martín, Tania, Bou, Germán, Fernández-López, María del Carmen, Gato, Eva, González-Pinto, Lucía, Martínez-Martínez, Luis, Outeda-García, Michelle, Pedraza-Merino, Rosa, Rodríguez-Coello, Arianna, Rodríguez-Pallares, Salud, Sánchez-Peña, Lucía, Vázquez-Ucha, Juan Carlos   +15 more
core   +2 more sources